How Gilead Is Building Durable Oncology and Immunology Franchises
Gilead today stands at an inflection point. Its HIV and broader virology business still account for roughly two-thirds of total revenue, eve...
Radio and PodcastLive Radio & PodcastsBusiness
The Bio Report
The Bio Report podcast, hosted by veteran journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
The Bio Report Podcast Guide
Listen to The Bio Report, a Business podcast by Levine Media Group. Stream 628 episodes in English, follow new audio stories, and play episodes online on Radio and Podcast.
Show Topic
Browse this show under Business podcasts.
Episodes
20 episodes are loaded now from a catalog of 628. More episodes can be opened from this page.
Discover More
Explore Business podcasts, United States podcasts and English podcasts.
Episodes
20 of 628 episodesProtecting the Brain After Stroke
Ischemic stroke remains one of the most devastating and resource‑intensive emergencies in medicine, with the physical removal of a clot, the...
Turning the Thymus into an Engine of Immune Tolerance in T1D and Beyond
Type 1 diabetes is still a disease we manage day‑to‑day rather than prevent, and today’s approaches do little to stop the immune system from...
Unlocking Major Targets with Mini Proteins
Most small molecule drugs and biologics miss a large group of important receptors in the body. These receptors, known as GPCRs, play big rol...
Addressing a Data Problem to Enable AI-Drug Discovery
AI’s promise in drug discovery is being held back by a simple but stubborn problem: the field doesn’t have enough of the right kind of lab-g...
Turning Multi Specific Antibody Design into an Engineering Discipline with AI
Multi-specific antibodies promise to unlock complex biology that conventional monoclonals can’t touch, but their added mechanisms of action...
Addressing the Treatment Gap in Ischemic Stroke
Acute ischemic stroke is both ubiquitous and undertreated. Only a small fraction of patients currently receive clot-busting drugs or mechani...
A Pipeline in a Product that Reimagines Control of Inflammation
Plasma gelsolin is an abundant, endogenous regulator of inflammation that is consumed during severe inflammatory insults. When levels fall t...
Building a Genetics Engine to Crack the Target Bottleneck
A chronic shortage of high‑quality targets remains one of the biggest constraints in drug discovery, even as therapeutic tools become more p...
Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug
Epigenetics, the layer of chemical switches that controls how genes are turned on and off, can act like cancer’s operating system when a sin...
Rewriting the Rules of Antibody Drug Design
Most marketed antibodies work as antagonists, simply shutting off a receptor, even though many immune, metabolic, and cancer pathways requir...
Mapping Cellular Stress Biology to Tackle Undruggable Targets
Cells continuously sense their environment and in response to stressors, adapt, recover, or die. Soley Therapeutics uses its AI platform to...
Turning Abandoned Drugs into Breakthroughs
Promising drugs can become abandoned or underused because of tolerability issues, poor drug‑like properties, or other fixable limitations, e...
Targeting Cancer Survival Genes in Solid Tumors
Most cancer therapies hit one or a few pathways that tumors can escape by mutating, activating alternative survival routes, or pumping drugs...
Addressing Treatment Gaps in Gout
Gout may be one of the oldest known forms of arthritis, but it remains widely misunderstood, undertreated, and a source of silent suffering...
An Off-the-Shelf Cell Therapy to Calm Cytokine Storms
Small molecule drugs and monoclonal antibodies often fall short at addressing severe inflammatory and immune‑mediated diseases. Mesoblast ha...
Slowing Disability in MS
Most existing therapies for multiple sclerosis do a good job of reducing relapses and inflammatory activity, but they largely fail to stop t...
Tuning, Rather than Blocking, Immunity in IBD
The treatment of inflammatory bowel disease currently relies on immunosuppressive therapies that often lose effectiveness, carry infection r...
Intercepting Cancer When DNA Surveillance Fails
Many people with the genetic condition Lynch syndrome live with the near‑certainty that they will one day develop cancer and have few option...
Targeting Psychosis in Alzheimer’s Disease
Alzheimer’s disease drug development has long focused on slowing memory loss, but for many families, the tipping point that makes home care...